Astra Zeneca LP Us Revenue and Competitors
Estimated Revenue & Valuation
- Astra Zeneca LP Us's estimated annual revenue is currently $67.3M per year.
- Astra Zeneca LP Us's estimated revenue per employee is $201,000
Employee Data
- Astra Zeneca LP Us has 335 Employees.
- Astra Zeneca LP Us grew their employee count by -3% last year.
Astra Zeneca LP Us's People
Name | Title | Email/Phone |
---|
Astra Zeneca LP Us Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $34M | 169 | 8% | N/A | N/A |
#2 | $8.4M | 42 | -28% | N/A | N/A |
#3 | $68.7M | 342 | 6% | N/A | N/A |
#4 | $49.4M | 246 | -10% | N/A | N/A |
#5 | $7.8M | 39 | 44% | N/A | N/A |
#6 | $148.3M | 738 | 8% | N/A | N/A |
#7 | $24.7M | 123 | 13% | N/A | N/A |
#8 | $0.8M | 8 | 14% | N/A | N/A |
#9 | $9M | 45 | 7% | N/A | N/A |
#10 | $3.8M | 19 | -50% | N/A | N/A |
What Is Astra Zeneca LP Us?
Astra Zeneca LP Us is a Pharmaceuticals company located in 1800 Concord Pike, Wilmington, Delaware, United States.
keywords:N/AN/A
Total Funding
335
Number of Employees
$67.3M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Astra Zeneca LP Us News
2022-04-06 - Daiichi Owes Seagen $41.8 Million Over Cancer Treatment ...
AstraZeneca, which markets Enhertu in the U.S., intervened in the suit. ... 2022 Bloomberg L.P. All rights reserved. Used with permission.
2022-04-06 - Daiichi Gets Rare Patent Board Rehearing in Drug Dispute (1)
Daiichi Sankyo Co. and AstraZeneca Pharmaceuticals LP were granted a rare administrative patent tribunal rehearing after the board rejected...
2022-03-22 - Oncology Overview: Acalabrutinib (Calquence) for Chronic ...
Acalabrutinib (Calquence; AstraZeneca Pharmaceuticals LP) is a ... The American Cancer Society estimates more than 60,000 new cases of...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $84.3M | 336 | 8% | N/A |
#2 | $122.2M | 337 | 5% | N/A |
#3 | $67.8M | 339 | 9% | N/A |
#4 | $55.3M | 340 | 9% | N/A |
#5 | $115.4M | 342 | -1% | N/A |